Overactive Bladder (OAB) — RepurpOS

Disease overview

Alterations

116

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

445

Natural agents

Natural products

Merged ranked

516

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Spontaneous fluctuation common; resolution in ~25% at 1 year; bladder training alone achieves 50-80% improvement in urgency frequency; OAB worsens with age without intervention

Best-intervention remission

Bladder training + pelvic floor exercises: 60-80% improvement (first-line guideline recommendation); anticholinergics/beta-3 agonist (mirabegron): 30-60% significant improvement; botulinum toxin A (OnabotulinumtoxinA, Botox): 30-50% complete continence at 12 weeks; sacral neuromodulation (InterStim): 72% success at 5 years

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — most patients receive pharmacotherapy as first-line without adequate behavioural therapy trial; anticholinergics overused in elderly

Primary barrier

framing/practice

Barrier detail: Behavioural interventions (pelvic floor training, bladder diary, timed voiding) are first-line by all guidelines but most patients receive anticholinergics immediately; anticholinergic cognitive burden in elderly patients is significant (dementia risk association with chronic use — JAMA Intern Med 2019); mirabegron has better cognitive safety profile but is underused relative to older anticholinergics

Last SoC change: 2021 — AUA/SUFU OAB guideline updated; implantable tibial nerve stimulator (NURO) added 2019; onabotulinumtoxinA for OAB since 2013; mirabegron (Myrbetriq) 2012; anticholinergics (oxybutynin) since 1975

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0006624

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Overactive Bladder may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 9, Phase 2: 31

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

116

Actionable

Pipeline Compounds (Top 6)

Fesoterodine, Gabapentin, Lidocaine, Onabotulinumtoxina, Propiverine, Ritobegron

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 116 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
ABCB1 ATP binding cassette subfamily B member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACHE acetylcholinesterase (Yt blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1A adrenoceptor alpha 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1B adrenoceptor alpha 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1D adrenoceptor alpha 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB3 adrenoceptor beta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGTR1 angiotensin II receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALB albumin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AVPR1A arginine vasopressin receptor 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AVPR1B arginine vasopressin receptor 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AVPR2 arginine vasopressin receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Adverse Events	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BCHE butyrylcholinesterase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BDNF brain derived neurotrophic factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1A calcium voltage-gated channel subunit alpha1 A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1B calcium voltage-gated channel subunit alpha1 B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1C calcium voltage-gated channel subunit alpha1 C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1D calcium voltage-gated channel subunit alpha1 D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1E calcium voltage-gated channel subunit alpha1 E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1F calcium voltage-gated channel subunit alpha1 F	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1G calcium voltage-gated channel subunit alpha1 G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1H calcium voltage-gated channel subunit alpha1 H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1I calcium voltage-gated channel subunit alpha1 I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1S calcium voltage-gated channel subunit alpha1 S	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D2 calcium voltage-gated channel auxiliary subunit alpha2delta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D4 calcium voltage-gated channel auxiliary subunit alpha2delta 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB1 calcium voltage-gated channel auxiliary subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB2 calcium voltage-gated channel auxiliary subunit beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB3 calcium voltage-gated channel auxiliary subunit beta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB4 calcium voltage-gated channel auxiliary subunit beta 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG1 calcium voltage-gated channel auxiliary subunit gamma 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG2 calcium voltage-gated channel auxiliary subunit gamma 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG3 calcium voltage-gated channel auxiliary subunit gamma 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG4 calcium voltage-gated channel auxiliary subunit gamma 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG5 calcium voltage-gated channel auxiliary subunit gamma 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG6 calcium voltage-gated channel auxiliary subunit gamma 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG7 calcium voltage-gated channel auxiliary subunit gamma 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCL2 C-C motif chemokine ligand 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH11 cadherin 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM1 cholinergic receptor muscarinic 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM2 cholinergic receptor muscarinic 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM3 cholinergic receptor muscarinic 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM4 cholinergic receptor muscarinic 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM5 cholinergic receptor muscarinic 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRNA4 cholinergic receptor nicotinic alpha 4 subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRNB2 cholinergic receptor nicotinic beta 2 subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRP C-reactive protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 Hours	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DDIT3 DNA damage inducible transcript 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Difference in the % of patients maintaining persistence between no intervention and HEI group	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
EDN1 endothelin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESR2 estrogen receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAAH fatty acid amide hydrolase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Gene expression (from RNA-sequencing)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
IGF1 insulin like growth factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL10 interleukin 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
INS insulin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Incidence of serious adverse events	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
KCNA3 potassium voltage-gated channel subfamily A member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KCNMA1 potassium calcium-activated channel subfamily M alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KLK3 kallikrein related peptidase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LEP leptin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Micturitions (1)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
NFKB1 nuclear factor kappa B subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NGF nerve growth factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOS2 nitric oxide synthase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRG1 neuregulin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Number of Participants With Cardio Vascular Safety	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
OPRM1 opioid receptor mu 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overactive Bladder Questionnaire (OAB-q short form)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ABEMACICLIB		Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ADAPALENE		Gene-targeted
ALBUMIN HUMAN-KJDA		Gene-targeted
ALFUZOSIN	inhibitor	Gene-targeted
ALFUZOSIN HYDROCHLORIDE	agonist	Gene-targeted
ALISKIREN		Gene-targeted
AMBENONIUM		Gene-targeted
AMBENONIUM CHLORIDE	inhibitor	Gene-targeted
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMISULPRIDE		Gene-targeted
AMITRIPTYLINE HYDROCHLORIDE	inhibitor	Gene-targeted
AMLODIPINE BESYLATE		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANGIOTENSIN II	agonist	Gene-targeted
ANGIOTENSIN II ACETATE	agonist	Gene-targeted
APIGENIN	inhibitor	Gene-targeted
ARGIPRESSIN	agonist; agonist	Gene-targeted
ARSENIC TRIOXIDE		Gene-targeted
ASCORBIC ACID		Gene-targeted
ASENAPINE		Gene-targeted
ASPARAGINE		Gene-targeted
ATAZANAVIR		Gene-targeted
ATENOLOL		Gene-targeted
ATORVASTATIN		Gene-targeted
ATORVASTATIN CALCIUM TRIHYDRATE		Gene-targeted
ATOSIBAN	inhibitor	Gene-targeted
AVATROMBOPAG		Gene-targeted
AZATHIOPRINE		Gene-targeted
AZILSARTAN KAMEDOXOMIL	inhibitor	Gene-targeted
AZILSARTAN MEDOXOMIL	inhibitor; inhibitor	Gene-targeted
AZITHROMYCIN		Gene-targeted
BACLOFEN		Gene-targeted
BENAZEPRIL		Gene-targeted
BENZGALANTAMINE GLUCONATE	inhibitor	Gene-targeted
BENZPHETAMINE		Gene-targeted
BEPRIDIL		Gene-targeted
BEPRIDIL HYDROCHLORIDE	blocker	Gene-targeted
BETAMETHASONE		Gene-targeted
BETHANIDINE		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Sources	Links
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
ADAPALENE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ALBUMIN HUMAN-KJDA Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ALFUZOSIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ALISKIREN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMBENONIUM Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMBENONIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMISULPRIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
APIGENIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ARGIPRESSIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ARSENIC TRIOXIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ASCORBIC ACID Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ASPARAGINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ATAZANAVIR Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
ATOSIBAN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AVATROMBOPAG Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AZATHIOPRINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
AZITHROMYCIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BACLOFEN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BENAZEPRIL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BENZGALANTAMINE GLUCONATE Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BEPRIDIL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
BISMUTH Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BOCEPREVIR Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BROMOCRIPTINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
BUPIVACAINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
CABAZITAXEL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
FESOTERODINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GABAPENTIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ONABOTULINUMTOXINA	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PROPIVERINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RITOBEGRON	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TAMSULOSIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VELUFENACIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AFACIFENACIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BURAPITANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CASOPITANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CINNAMON	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DESMOPRESSIN	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DEXMECAMYLAMINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DULOXETINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ELIAPIXANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ESTRIOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
GEFAPIXANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
GISADENAFIL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
INCOBOTULINUMTOXINA	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
JTS-653	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LETIBOTULINUMTOXINA	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NALTALIMIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ONO-8539	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
PREGABALIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SAF312	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SENREBOTASE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SERLOPITANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SOLABEGRON	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TARAFENACIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TARANABANT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TORSEMIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
VARDENAFIL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
XEN-D0501	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Sources	Links
ABEMACICLIB Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
ACETAZOLAMIDE Repurposing via ABCB1	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
ADAPALENE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ALBUMIN HUMAN-KJDA Repurposing via ALB	Small molecule	Approved	Strong	95	DGIdb	—
ALFUZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ALISKIREN Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
AMBENONIUM Repurposing via ACHE	Small molecule	Approved	Strong	95	DGIdb	—
AMBENONIUM CHLORIDE Repurposing via ACHE	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	DGIdb	—
AMISULPRIDE Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
AMLODIPINE BESYLATE Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
AMPHETAMINE Repurposing via ABCB1	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
APIGENIN Repurposing via ACHE	Small molecule	Approved	Strong	95	DGIdb	—
ARGIPRESSIN Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ARSENIC TRIOXIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ASCORBIC ACID Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
ASENAPINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	DGIdb	—
ASPARAGINE Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
ATAZANAVIR Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
ATENOLOL Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
ATORVASTATIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
ATOSIBAN Repurposing via AVPR1A	Small molecule	Approved	Strong	95	DGIdb	—
AVATROMBOPAG Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
AZATHIOPRINE Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
AZITHROMYCIN Repurposing via ABCB1	Small molecule	Approved	Strong	95	DGIdb	—
BACLOFEN Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
BENAZEPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	DGIdb	—
BENZGALANTAMINE GLUCONATE Repurposing via ACHE	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BENZPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	DGIdb	—
BEPRIDIL Repurposing via CACNA1A	Small molecule	Approved	Strong	95	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1B	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via ACHE	Small molecule	Approved	Strong	95	DGIdb	—
BETHANIDINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	DGIdb	—

Natural Products

33 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Links
Vitamin D3 Natural product Clinical trial publication Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenac… Clinical trial publication Comparing Vitamin D Supplementation Versus Placebo for Urgency Urinary… Meta Analysis Higher intakes of vitamin D, protein and potassium are significantly as…	Nutraceutical	Preclinical	Emerging	10	5 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT07513363 — The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency (NOT_YET_RECRUITING) NA NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet (RECRUITING) NA NCT05709990 — Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children (COMPLETED) NA NCT01971801 — Vitamin D Supplementation in Older Adults With Urinary Incontinence (COMPLETED) NA NCT06489951 — Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker (COMPLETED) NA Published literature Clinical trial publication Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial (The Journal of urology, 2024) Clinical trial publication Comparing Vitamin D Supplementation Versus Placebo for Urgency Urinary Incontinence: A Pilot Study (Journal of the American Geriatrics Society, 2019) CT.gov search · Cochrane · PubMed	PubChem
Vitamin C Natural product Human Study Efficacy and safety of a new complementary and alternative medicine (CA… Meta Analysis Higher intakes of vitamin D, protein and potassium are significantly as…	Nutraceutical	Phase II	Emerging	10	2 trials 1 Trial pubs View evidence Registry trials NCT00578097 — Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder (TERMINATED) PHASE2 NCT06080217 — RF in the Treatment OAB in UUI- a Prospective Randomized Placebo Controlled Study (UNKNOWN) NA CT.gov search · Cochrane · PubMed	PubChem
Cinnamon Natural product Human Study Efficacy of cinnamon patch treatment for alleviating symptoms of overac… Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Botanical	Preclinical	Emerging	7	1 Trial pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Potassium Natural product Systematic review Emerging pharmacological targets in overactive bladder therapy: experim… Meta Analysis Higher intakes of vitamin D, protein and potassium are significantly as…	Nutraceutical	Approved	Emerging	7	1 trials 4 Trial pubs View evidence Registry trials NCT05519072 — Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA (RECRUITING) PHASE4 Published literature Systematic review Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences (International urogynecology journal and pelvic floor dysfunction, 2008) CT.gov search · Cochrane · PubMed	PubChem
Lactobacillus Natural product Human Study . The use of Lactobacillus-containing feminine products was associated…	Probiotic	Preclinical	Emerging	7	4 trials 2 Trial pubs View evidence Registry trials NCT07635212 — Efficacy of Probiotics for OAB Patients With Anxiety (NOT_YET_RECRUITING) NA NCT06546189 — Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial (RECRUITING) NA NCT03904407 — Optimizing Overactive Bladder Treatment (COMPLETED) NA NCT05013593 — Red Clover Isoflavones in Postmenopausal Women With Urge Urinary Incontinence and Overactive Bladder (COMPLETED) NA CT.gov search · Cochrane · PubMed	—
Resveratrol Natural product Animal Study Resveratrol treatment could be an option to prevent obesity-associated… Human Study The management of children and adolescents with overactive bladder refr… Human Study Transcutaneous electrical nerve stimulation use in children with incont…	Food compound	Preclinical	Emerging	7	3 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Cannabidiol Natural product Human Study THC/CBD oromucosal spray has shown to be effective in improving overact…	Food compound	Phase III	Emerging	2	2 trials View evidence Registry trials NCT00678795 — A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis (COMPLETED) PHASE3 NCT05106504 — Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease (UNKNOWN) CT.gov search · Cochrane · PubMed	PubChem
Pumpkin Natural product Clinical trial publication Cucurbita pepo-Rhus aromatica-Humulus lupulus Combination Reduces Overa… Human Study Efficacy and safety of a new complementary and alternative medicine (CA… Human Study Pumpkin seed oil extracted from C. maxima has the potential for prevent…	Nutraceutical	Preclinical	Emerging	0	1 trials 1 Trial pubs View evidence Registry trials NCT06944392 — Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function (RECRUITING) NA Published literature Clinical trial publication Cucurbita pepo-Rhus aromatica-Humulus lupulus Combination Reduces Overactive Bladder Symptoms in Women - A Noninterventional Study (Planta medica, 2019) CT.gov search · Cochrane · PubMed	—
Japanese Traditional Herbal Formula: Gosha-Jinki-Gan Natural product Human Study Gosha-jinki-gan (GJG), a traditional Chinese medicine, may have therape… Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Catechin Natural product Animal Study "Green tea catechins decrease oxidative stress in surgical menopau… Animal Study Catechins prevents experimentally-induced hyperactive bladder in rats.	Nutraceutical	Preclinical	Emerging	0	2 pubs View evidence CT.gov search · Cochrane · PubMed	—
Protein Supplement Natural product Meta Analysis Higher intakes of vitamin D, protein and potassium are significantly as…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Hops Natural product Human Study Cucurbita pepo-Rhus aromatica-Humulus lupulus combination reduces overa…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Chili Pepper Natural product Human Study Efficacy and safety of a new complementary and alternative medicine (CA…	Nutraceutical	Preclinical	Emerging	0	2 pubs View evidence CT.gov search · Cochrane · PubMed	—
Pumpkin Seed Oil/Meal Natural product Human Study Pumpkin seed oil extracted from C. maxima has the potential for prevent… Human Study Cucurbita pepo-Rhus aromatica-Humulus lupulus combination reduces overa… Human Study Efficacy and safety of a new complementary and alternative medicine (CA…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Cannabis Natural product Human Study THC/CBD oromucosal spray has shown to be effective in improving overact…	Nutraceutical	Phase III	Emerging	0	2 trials View evidence Registry trials NCT00678795 — A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis (COMPLETED) PHASE3 NCT05106504 — Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease (UNKNOWN) CT.gov search · Cochrane · PubMed	—
Delta-Tetrahydrocannabinol (THC) Natural product Human Study THC/CBD oromucosal spray has shown to be effective in improving overact…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Achyranthes Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Alisma Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Cornus Officinalis Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Dioscorea Opposita Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Peony Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	—	—
Plantain Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	—	—
Rehmannia Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	—	—
Wolfiporia Extensa Natural product Human Study The Japanese multi-herbal formual known as gosha-jinki-gan could be a s…	Nutraceutical	Preclinical	Emerging	0	—	—
Estriol Natural product Human Study Vaginal estriol therapy significantly reduces symptoms of urinary urgen…	Nutraceutical	Preclinical	Emerging	0	—	—
Tea Natural product Animal Study "Green tea catechins decrease oxidative stress in surgical menopau…	Nutraceutical	Preclinical	Emerging	0	—	—
Hydrogen Water Natural product Animal Study Hydrogen water could ameliorate bladder dysfunction secondary to bladde…	Nutraceutical	Preclinical	Emerging	0	—	—
Genistein Natural product Animal Study Soy isoflavone replacement may be useful to treat or prevent overactive…	Food compound	Preclinical	Emerging	0	—	PubChem
Isoflavones Natural product Animal Study Soy isoflavone replacement may be useful to treat or prevent overactive…	Nutraceutical	Preclinical	Emerging	0	—	—
Soy Natural product Animal Study Soy isoflavone replacement may be useful to treat or prevent overactive…	Nutraceutical	Preclinical	Emerging	0	—	—
Saw Palmetto Natural product Commentary Saw palmetto extract at clinically relevant doses may exert a direct ef…	Nutraceutical	Preclinical	Emerging	0	—	—
Goldenrod Natural product Sumac (R. aromatica) and goldenrod (S. virgaurea) inhibit muscarinic re…	Nutraceutical	Preclinical	Emerging	0	—	—
Sumac Natural product Sumac (R. aromatica) and goldenrod (S. virgaurea) inhibit muscarinic re…	Nutraceutical	Preclinical	Emerging	0	—	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.